Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR

Christelle de la Fouchardière,Yann Godbert,Cécile Dalban,Frédéric Illouz,Johanna Wassermann,Christine Do Cao,Stéphane Bardet,Slimane Zerdoud,Cécile N Chougnet,Mohamed Zalzali,Danielle Benisvy,Patricia Niccoli,Laurence Digue,Livia Lamartina,Paul Schwartz,Françoise Borson Chazot,Julien Gautier,David Pérol,Sophie Leboulleux

European Journal of Cancer（2021）

引用 8|浏览49

暂无评分

摘要

•MKI tolerance improvement and prevention of MKI early discontinuation are needed.•PAZOTHYR investigated intermittent versus continuous pazopanib administration.•Intermittent pazopanib scheme did not significantly improve efficacy or tolerance.•Intermittent administration scheme cannot be recommended outside clinical trials.

查看译文

关键词

Thyroid cancer,RAI refractory thyroid cancer,Tyrosine kinase inhibitor,Pazopanib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要